2023
Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study — United States, August 19, 2022–March 31, 2023
Dalton A, Diallo A, Chard A, Moulia D, Deputy N, Fothergill A, Kracalik I, Wegner C, Markus T, Pathela P, Still W, Hawkins S, Mangla A, Ravi N, Licherdell E, Britton A, Lynfield R, Sutton M, Hansen A, Betancourt G, Rowlands J, Chai S, Fisher R, Danza P, Farley M, Zipprich J, Prahl G, Wendel K, Niccolai L, Castilho J, Payne D, Cohn A, Feldstein L, Group C, Group C, Saadeh K, Snyder R, Anderson M, Anguiano V, Nadle J, Rothrock G, Jones S, Duval L, Herlihy R, Stringer G, Weber R, Phan Q, Sosa L, Meek J, Lee M, Morrow A, Willut C, Carlson J, Kamis K, Nishiyama M, Simien G, Colasanti J, van der Woude T, Archer R, Finn L, Lam J, Moulton B, Peterson E, Bolan R, Garcia-Lopez G, Como-Sabetti K, Ruff A, Schneider D, Robinson T, Anderson B, Engesser K, McGuire S, Rowe A, Pride C, Mitchell J, Tourkina Y, Cieslak P, Fill M, Wiedeman C, Dumyati G, Felsen C, Lewnard J, Akoko B, Mansilla-Dubon K, Ndi D, Talbot H, Tiwari S, Wyatt D. Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study — United States, August 19, 2022–March 31, 2023. MMWR Morbidity And Mortality Weekly Report 2023, 72: 553-558. PMID: 37200229, PMCID: PMC10205167, DOI: 10.15585/mmwr.mm7220a3.Peer-Reviewed Original ResearchConceptsAdjusted vaccine effectivenessVaccine effectivenessCase-control studyFull vaccinationEmerging Infections Program sitesEmergency use authorizationDuration of protectionPrevention of smallpoxImmunocompetent participantsImmunocompromised participantsControl patientsImmunization PracticesPartial vaccinationIntradermal injectionSubcutaneous injectionVaccinationMonkeypox casesAdministration routeDrug AdministrationVaccine accessLaboratory capacityTransgender adultsVaccineTransgender personsAdvisory Committee
2022
Epidemiologic and Clinical Features of Children and Adolescents Aged <18 Years with Monkeypox — United States, May 17–September 24, 2022
Hennessee I, Shelus V, McArdle C, Wolf M, Schatzman S, Carpenter A, Minhaj F, Petras J, Cash-Goldwasser S, Maloney M, Sosa L, Jones S, Mangla A, Harold R, Beverley J, Saunders K, Adams J, Stanek D, Feldpausch A, Pavlick J, Cahill M, O’Dell V, Kim M, Alarcón J, Finn L, Goss M, Duwell M, Crum D, Williams T, Hansen K, Heddy M, Mallory K, McDermott D, Cuadera M, Adler E, Lee E, Shinall A, Thomas C, Ricketts E, Koonce T, Rynk D, Cogswell K, McLafferty M, Perella D, Stockdale C, Dell B, Roskosky M, White S, Davis K, Milleron R, Mackey S, Barringer L, Bruce H, Barrett D, D’Angeli M, Kocharian A, Klos R, Dawson P, Ellington S, Mayer O, Godfred-Cato S, Labuda S, McCormick D, McCollum A, Rao A, Salzer J, Kimball A, Gold J, Group C, Group C, Group C, Berumen R, Cosentino G, Getabecha S, Glaser C, Grosgebauer K, Harriman K, Haw M, Kamali A, Kath C, Kim E, Lewis L, Sachdev D, Salas M, Stainken C, Wadford D, Peters P, Vaidya A, Group C, Adkins S, Baird ;, Barrios L, Beeson A, Blackburn D, Borah B, Click E, Davidson W, Galang R, Hufstetler K, Hutchins H, Kourtis A, Miller M, Morris S, Olsen E, Roth N, Sims E, Chatham-Stephens K. Epidemiologic and Clinical Features of Children and Adolescents Aged <18 Years with Monkeypox — United States, May 17–September 24, 2022. MMWR Morbidity And Mortality Weekly Report 2022, 71: 1407-1411. PMID: 36331124, PMCID: PMC9639439, DOI: 10.15585/mmwr.mm7144a4.Peer-Reviewed Original ResearchConceptsMale-to-male sexual contactPublic health priorityLt;18 yearsJurisdictional health departmentsSkin-to-skin contactChildren aged 0Adolescents aged <Intensive care unit (ICU)-level careUnited StatesHealth priorityNon-HispanicHealth departmentsPrevention informationMonkeypox virusAged 0Prevent additional infectionsRisk factorsCareAdolescentsClinical featuresMonkeypox vaccineChildrenLt;18Monkeypox casesSexual contact